Optimal
Research, a service of PPD’s Accelerated
Enrollment Solutions (AES) business unit, was named the top clinical
trial network at the 12th annual Vaccine
Industry Excellence (ViE) Awards during the 2019 World Vaccine
Congress in Washington, D.C.
The ViE awards celebrate the outstanding achievements of organizations
and individuals setting high standards of excellence and advocacy in the
vaccine industry.
Optimal’s Vaccine Centers of Excellence is the world’s largest vaccine
site network, accentuated by accelerated patient enrollment services,
advanced lab capabilities including peripheral blood mononuclear cells
(PBMC) processing, and specialized vaccine services – all delivered
under a results-based contracting model that offers cost and time
certainty in trial delivery.
“This recognition by industry peers reflects our Vaccine Centers of
Excellence’s success in supporting multiple and diverse clinical phase
and outcomes trials,” said Krystyna Kowalczyk, chief operating officer
for Optimal Oncology and Vaccines Services. “This award acknowledges our
team’s expertise in helping clients quickly enroll patients and maintain
extremely high retention rates.”
Examples of Optimal’s delivery success for clients include recently
registering more than 350 subjects in nine business days for a research
study for respiratory syncytial virus (RSV) that included specialized
lab processing for each randomized patient, all while maintaining a 97
percent subject retention rate across all research study populations.
Overall, Optimal has recruited more than 70,000 patients for more than
850 vaccine trials.
About AES
Accelerated Enrollment Solutions is a business unit of Pharmaceutical
Product Development, LLC (PPD)
that offers clients and contract research organizations best-in-class
site and enrollment solutions through its service brands Synexus,
Acurian and Optimal, as well as in combination with PPD’s
industry-leading global clinical development services. These solutions
are available as discrete services or integrated to provide a cohesive
and highly differentiated trial acceleration strategy for insourced or
outsourced clinical studies, all under performance-based commercial
terms. For more information, visit www.globalAES.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005586/en/